Tratamiento de la neumonía comunitaria

Archivos de Bronconeumologia

Volumn 34, Issue SUPPL. 2, 1998, Pages 50-56

  Dorca, J ^a   Fernandez S ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

COMMUNICABLE DISEASE; HUMAN; PNEUMONIA; REVIEW;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA;

EID: 0012673728     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol 1997; 33: 240-246.
2. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993 148: 1.418-1.426.
3. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-350.
4. Dorca J, Manresa F. Community-acquired pneumonia: initial management and empiric treatment. En: Pneumonia. Eur Respir Mon 1997; 3: 36-55.
5. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1.618-1.624.
6. Woodhead M. Community-acquired guidelines-an international comparison: a view from Europe. Chest 1998; 113: 183-187.
7. Woodhead M. Management of pneumonia in the outpatient setting. Semm Respir Infect 1998; 13: 8-16.
8. Andrews BE. Community-acquired pneumonia in adults in British hospitals in 1982-3: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Healts Laboratory Service. Q J Med 1987; 62: 195-220.
9. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5 year prospective study. Rev Infect Dis 1989; 11: 586-599.
10. Macfarlane JT. Community-acquired pneumonia. Br J Dis Chest 1987; 81: 116-127.
11. Woodhead MA, Macfarlane JT, Rodgers FG et al. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985; 10: 204-210.
12. Ortqvist A, Sterner G, Nilsson AJ. Severe community-acquired pneumonia: factor of influencing the need of intensive care treatment and prognosis. Scan J Infect Dis 1985; 17: 377-386.
13. Pachon J, Prados MD, Capote F et al. Severe community-acquired pneumonia: etiology, prognosis and treatment. Am Rev Respir Dis 1990; 142: 369-373.
14. Sorensen J, Forsberg P, Hakanson E et al. A new diagnostic approach to the patient with severe community-acquired pneumonia. Scan J Infect Dis 1989; 21: 33-41.
15. Torres A, Serra-Batlles J, Ferrer A et al. Severe community-acquired pneumonia. Am Rev Respir Dis 1991; 144: 312-318.
16. Torres A, Dorca J, Zalacaín R et al. Community-acquired pneumonia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 1.456-1.461.
17. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infet Dis 1992; 15: 77-83.
18. Gold HS, Moellering RC. Antimicrobial drug resistance. N Engl J Med 1996; 335: 1.445-1.453.
19. Manresa F, Dorca J. Microbial aetiology and bacterial resistance. European perspective on community-acquired pneumonia. Sem Respir Infect 1998 (en prensa).
20. Baquero F. Pneumococcal resistance to beta-lactam antibiotics: A global geographic overview. Antimicrob Drug Resistance 1995; 1: 115-120.
21. Breiman RF, Butler JC, Tenover C, Elliot JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271: 1.831-1.835.
22. Liñares J, Alonso T, Pérez JL, Ayats J, Dormínguez MA, Pallarés R et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemoter 1992; 30: 279-288.
23. Baquero F, Martínez Beltrán J, Loza F. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991; 28: 31-38.
24. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996; 38 (Supl A): 117-132.
25. Goldstein FW, Acar JF. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38 (Supl A): 71-84.
26. Pallarés R, Gudiol F, Liñares J, Ariza J, Rufí G, Dorca J et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. New Engl J Med 1987; 317: 18-22.
27. Nava JM, Bella F, Garau J et al. Predictive factors for invasive disease due to penicillin-resistant pneumococci. J Infect Dis 1994; 19: 884-890.
28. Klugman KP. The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxhella catarrhalis. J Antimicrob Chemoter 1996; 38 (Supl A): 133-140.
29. Musher DM, Spindel SJ. Community-acquired pneumonia. Curr Clin Topics Infect Dis 1996; 16: 102-124.
30. Friedland IR. Comparison of response to antimicrobial therapy of penicillin-resistant and penicilllin-susceptible pneumococcal disease. Pediatr Infect Dis J 1996; 14: 885-990.
31. Pallarés R, Liñares J, Vadillo M, Cabellos C, Manresa F et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New Eng J Med 1995; 33: 474-480.
32. Cometta A, Baumgartner JD, Lew et al. Prospective randomized comparison of imipenem monotherapy with imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in non-neutropenic patiens. Antimicrob Agents Chemother 1994; 38: 1.309-1.313.
33. Segreti J, Meyer P, Kapell K. In vitro activity of macrolides against intracellular Legionella pneumophila. Diagn Microbiol Infect Dis 1996; 25: 123-126.
34. Fraser KL, Grossman RF. What new antibiotics to offer in the out-patient setting. Semm Respir Infect 1998; 13: 24-35.
35. Malini H, Lamb HM. Trovafloxacin. Drugs 1997; 54: 435-445.
36. Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997; 53: 817-824.
37. Johnson CC, Slavoski L, Schwartz M et al. In vitro activity of quinupristin/dalfopristin against antibiotic-resistant strains of Streptococcus pneumonias and Enterococci. Diagn Microbiol Infect Dis 1995; 21: 169-173.
38. Bryson HM, Spencer CM. Quinupristin/dalfopristin. Drugs 1996; 52: 406-415.